Ranked #4,076 of 8,699 institutional investors
GSK plc
London, X0
$422M
US stock portfolio at live prices · today −$6.1M (−1.44%)
Market closed. Prices as of Nov 20, 7:11 AM ET
- Value at quarter end (Q3 2026)
- $497M
- Change from Q2 2026
- −$105.2M (−17.47%)
- Positions
- 12 · 0 new, 0 sold out
- Filed
- Nov 5, 2026
Not counted in the ranking: none$144M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesVIR 18.0%BNTX 12.9%WVE 11.8%IDYA 8.27%LYEL 4.87%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| VIR Vir Biotechnology, Inc. | 8,550,954 | $75.8M | 18.0% | Unchanged |
| BNTX BioNTech SE | 668,526 | $54.4M | 12.9% | Reduced −25% |
| WVE Wave Life Sciences, Inc. | 18,245,691 | $49.6M | 11.8% | Unchanged |
| IDYA IDEAYA Biosciences, Inc. | 1,333,333 | $34.9M | 8.27% | Unchanged |
| LYEL Lyell Immunopharma, Inc. | 1,512,659 | $20.5M | 4.87% | Unchanged |
| CYTK Cytokinetics, Incorporated | 340,434 | $17.5M | 4.15% | Unchanged |
| SPRO Spero Therapeutics, Inc. | 9,190,606 | $7.6M | 1.80% | Unchanged |
| FULC Fulcrum Therapeutics, Inc. | 1,785,714 | $6.6M | 1.57% | Unchanged |
| BCYC Bicycle Therapeutics plc | 1,529,561 | $4.7M | 1.11% | Unchanged |
| NKTX Nkarta, Inc. | 3,150,732 | $3.5M | 0.84% | Unchanged |
| RGNX REGENXBIO Inc. | 271,456 | $1.9M | 0.46% | Unchanged |
| CVRX CVRx, Inc. | 1,007,583 | $537K | 0.13% | Unchanged |